sgm-101

mAbexperimentalImaging agent

Chemistry & pharmacology

Multi-specific
No
Imaging
BM104

Oral

No

Parenteral

No

Topical

No

Also known as

  • sgm-101

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06280690Phase 2Jan 31, 2024Leiden University
NCT05965817Phase 2Dec 1, 2023Leiden University
NCT04755920Phase 2Apr 30, 2021Leiden University, Medical Center Haaglanden, Surgimab
NCT04737213Phase 2Nov 1, 2020Erasmus University Rotterdam, Leiden University, Surgimab
NCT04315467Phase 1May 31, 2020University of Pennsylvania
NCT04642924Phase 2/Phase 3 (Phase 3)Oct 22, 2019Erasmus University Rotterdam, Free University of Amsterdam, Leiden University, Maastricht University, Medical Center Haaglanden, Quest Diagnostics, Surgimab
NCT03659448Phase 3Dec 31, 2018Leiden University, Surgimab
NCT02973672Phase 1/Phase 2 (Phase 2)Jan 1, 2016Erasmus University Rotterdam, Leiden University, Maastricht University, Surgimab
NCT02784028N/ADec 31, 2014University of Montpellier
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Leiden UniversityAcademic/Hospital7522016
SurgimabFor profit5222016
Erasmus University RotterdamAcademic/Hospital3022016
Maastricht UniversityAcademic/Hospital2022016
Medical Center HaaglandenAcademic/Hospital2022019
Free University of AmsterdamAcademic/Hospital1012019
Quest DiagnosticsFor profit1012019
University of MontpellierAcademic/Hospital1112014
University of PennsylvaniaAcademic/Hospital1112020
9 organizations
Page 1 / 1